Cardiac Multimodality Imaging in Hypertrophic Cardiomyopathy: What to Look for and When to Image

Curr Cardiol Rev. 2023;19(5):1-18. doi: 10.2174/1573403X19666230316103117.

Abstract

Hypertrophic cardiomyopathy (HCM), now recognized as a common cardiomyopathy of complex genomics and pathophysiology, is defined by the presence of left ventricular hypertrophy of various morphologies and severity, significant hemodynamic consequences, and diverse phenotypic, both structural and clinical, profiles. Advancements in cardiac multimodality imaging, including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography, with and without angiography have greatly improved the diagnosis of HCM, and enable precise measurements of cardiac mass, volume, wall thickness, function, and physiology. Multimodality imaging provides comprehensive and complementary information and hasemerged as the bedrock for the diagnosis, clinical assessment, serial monitoring, and sudden cardiac death risk stratification of patients with HCM. This review highlights the role of cardiac multimodality imaging in the modern diagnosis and management of HCM.

Keywords: Hypertrophic cardiomyopathy; cardiac computed tomography; cardiac death risk; cardiac magnetic resonance imaging; echocardiography; multimodality imaging.

Publication types

  • Review

MeSH terms

  • Cardiomyopathies*
  • Cardiomyopathy, Hypertrophic* / diagnostic imaging
  • Echocardiography
  • Heart
  • Humans
  • Magnetic Resonance Imaging